Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Gujarat Terce Laboratories's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gujarat Terce Laboratories Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gujarat Terce Laboratories's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Gujarat Terce Laboratories's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gujarat Terce Laboratories (BOM:524314) has a Buyback Yield % of -3.28 as of Aug. 08, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Gujarat Terce Laboratories and its competitors. According to the industry distribution chart, Gujarat Terce Laboratories ranks #170 out of 277 companies in the Drug Manufacturers industry, placing it in the top 61.4%.
Is Gujarat Terce Laboratories' Buyback Yield % too high?
Gujarat Terce Laboratories' current Buyback Yield % is -3.28. Based on the distribution chart, Gujarat Terce Laboratories ranks #170 out of 277 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Gujarat Terce Laboratories has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Gujarat Terce Laboratories' Buyback Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Gujarat Terce Laboratories ranks #170 out of 277 companies for Buyback Yield %. This places Gujarat Terce Laboratories in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Gujarat Terce Laboratories and its competitors. Gujarat Terce Laboratories's current Buyback Yield % is -3.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gujarat Terce Laboratories stock overvalued right now?
Gujarat Terce Laboratories (BOM:524314) has a current Buyback Yield % of -3.28. The current Buyback Yield % is -3.28. Gujarat Terce Laboratories' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Gujarat Terce Laboratories (BOM:524314), the current Buyback Yield % is -3.28 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gujarat Terce Laboratories Ltd is an Indian company having business in the medical and pharmaceutical preparations. It is engaged in the manufacturing of tablets, capsules, syrup, and injections. It offers branded as well as generic formulations covering different therapeutic areas such as antibiotics, respiratory, nutraceuticals, gastrointestinal, antifungal, and many more. Some of the main brands are Acolate, Tynol, DFS, Resplash, Aziter, and others.
34GF Score
Get the complete analysis for BOM:524314
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524314 has been successfully added to your 
